Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of KarXT in Children and Adolescents With Psychiatric Disorders
NCT07424404Phase 3Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Apr 2026
- Primary completion
- Mar 2030
- Countries
- 11
01
Overview
A Phase 3 trial of xanomeline in schizophrenia, Autism Spectrum Disorder (ASD), sponsored by Karuna Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
xanomeline
03
Conditions
schizophreniaAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07424404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07424404.